ALFYX | VEXRX | ALFYX / VEXRX | |
Total Expense Ratio | 1.22 | 0.34 | 359% |
Annual Report Gross Expense Ratio | 1.22 | 0.34 | 359% |
Fund Existence | 21 years | 23 years | - |
Gain YTD | -12.786 | -14.722 | 87% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000000 | 50000 | 2,000% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 526M | 19.8B | 3% |
Annual Yield % from dividends | 0.38 | 0.56 | 67% |
Returns for 1 year | -3.77 | -12.82 | 29% |
Returns for 3 years | -4.16 | -9.40 | 44% |
Returns for 5 years | 36.63 | 15.80 | 232% |
Returns for 10 years | -23.43 | -1.76 | 1,328% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
XBI | 79.10 | 1.46 | +1.88% |
SPDR® S&P Biotech ETF | |||
CHI | 9.78 | 0.17 | +1.77% |
Calamos Convertible Opportunities and Income Fund | |||
SBIO | 28.02 | 0.45 | +1.63% |
ALPS Medical Breakthroughs ETF | |||
BCDF | 28.54 | 0.12 | +0.44% |
Horizon Kinetics Blockchain Dev ETF | |||
FEP | 41.67 | -0.06 | -0.14% |
First Trust Europe AlphaDEX® ETF |